Maxalt Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Maxalt, and what generic alternatives are available?
Maxalt is a drug marketed by Organon Llc and Organon and is included in two NDAs.
The generic ingredient in MAXALT is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Maxalt
A generic version of Maxalt was approved as rizatriptan benzoate by AUROBINDO PHARMA LTD on December 31st, 2012.
Summary for Maxalt
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 114 |
Clinical Trials: | 9 |
Patent Applications: | 725 |
Drug Prices: | Drug price information for Maxalt |
What excipients (inactive ingredients) are in Maxalt? | Maxalt excipients list |
DailyMed Link: | Maxalt at DailyMed |
Recent Clinical Trials for Maxalt
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Robert W. Baloh | Phase 2/Phase 3 |
Henry M. Jackson Foundation for the Advancement of Military Medicine | N/A |
Beth Israel Deaconess Medical Center | Phase 4 |
Pharmacology for Maxalt
Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for Maxalt
Paragraph IV (Patent) Challenges for MAXALT
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MAXALT | Tablets | rizatriptan benzoate | 5 mg and 10 mg | 020864 | 1 | 2004-09-02 |
US Patents and Regulatory Information for Maxalt
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Organon Llc | MAXALT | rizatriptan benzoate | TABLET;ORAL | 020864-001 | Jun 29, 1998 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Organon | MAXALT-MLT | rizatriptan benzoate | TABLET, ORALLY DISINTEGRATING;ORAL | 020865-002 | Jun 29, 1998 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Organon Llc | MAXALT | rizatriptan benzoate | TABLET;ORAL | 020864-002 | Jun 29, 1998 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Organon | MAXALT-MLT | rizatriptan benzoate | TABLET, ORALLY DISINTEGRATING;ORAL | 020865-001 | Jun 29, 1998 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Maxalt
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Organon Llc | MAXALT | rizatriptan benzoate | TABLET;ORAL | 020864-002 | Jun 29, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Organon Llc | MAXALT | rizatriptan benzoate | TABLET;ORAL | 020864-002 | Jun 29, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Organon Llc | MAXALT | rizatriptan benzoate | TABLET;ORAL | 020864-001 | Jun 29, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Organon Llc | MAXALT | rizatriptan benzoate | TABLET;ORAL | 020864-001 | Jun 29, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Maxalt
See the table below for patents covering Maxalt around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2238140 | DERIVES DE L'IMIDAZOLE, DU TRIAZOLE ET DU TETRAZOLE (IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES) | ⤷ Try a Trial |
Greece | 3025026 | ⤷ Try a Trial | |
Slovakia | 278998 | ⤷ Try a Trial | |
Croatia | P930777 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | ⤷ Try a Trial |
Ireland | 920342 | ⤷ Try a Trial | |
European Patent Office | 0497512 | Dérivés d'imidazole, triazole et tétrazole (Imidazole, triazole and tetrazole derivatives) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for Maxalt
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0497512 | 98C0037 | France | ⤷ Try a Trial | PRODUCT NAME: RIZATRIPTAN BENZOATE; REGISTRATION NO/DATE IN FRANCE: NL 23 695 DU 19980817; REGISTRATION NO/DATE AT EEC: 21 815 DU 19980211 |
0497512 | 28/1998 | Austria | ⤷ Try a Trial | PRODUCT NAME: RIZATRIPTAN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE RIZATRIPTANBENZOAT; NAT. REGISTRATION NO/DATE: 1-22636 - 1-22639 19980709; FIRST REGISTRATION: NL 21815 - 21818 19980211 |
0497512 | C980019 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: RIZATRIPTAN, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZOND ER RIZATRIPTAN-BENZOAAT; REGISTRATION NO/DATE: RVG 21815 - RVG 21818 19980211 |
0497512 | 9891028-4 | Sweden | ⤷ Try a Trial | PRODUCT NAME: RIZATRIPTAN, N.N-DIMETYL-2-(5-(1, 2, 4-TRIAZOL-1-YLMETYL)-1H-INDOL-3-YL)ET)-1H-I, EVENTUELLT I FORM AV ETT FARMACEUTISKT GODTAGBART SALT, SPECIELLT DA RIZATRIPTANBENSOAT |
0497512 | 99C0011 | Belgium | ⤷ Try a Trial | PRODUCT NAME: RIZATRIPTAN BENZOAS EQ. RIZATRIPTAN; REGISTRATION NO/DATE: 922 IS 181 F 3 19981130; FIRST REGISTRATION: NL RVG 21815 19980211 |
0497512 | SPC/GB98/035 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: RIZATRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY RIZATRIPTAN BENZOATE; REGISTERED: NL 21815 19980211; NL 21816 19980211; NL 21817 19980211; NL 21818 19980211; UK 00025/0369 19980624; UK 00025/0370 19980624; UK 00025/0371 19980624; UK 00025/0372 19980624 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |